NCT03330197 · REGISTRY CONDITION SEARCH

A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE1, PHASE2
Status at capture: TERMINATED
Registry last update: 2025-08-12

This research study involves an investigational product: Ad-RTS-hIL-12 given with veledimex for production of human IL-12. IL-12 is a protein that can improve the body's natural response to disease by enhancing the ability of the immune system to kill tumor cells and may interfere with blood flow to the tumor. The main purpose of this study is to evaluate the safety and tolerability of a single tumor injection of Ad-RTS-hIL-12 given with oral veledimex in the pediatric population.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

The Safety and Tolerability of Intratumoral Ad-RTS-hIL-12 and Veledimex as Measured by Dose Limiting Toxicities and Compliance.

→

outcome · POSTED

To Measure the Veledimex in Blood and Brain Tumor by Using the LC-MS Method

→

outcome · POSTED

Overall Survival (OS)

→

outcome · POSTED

Measure Immune Response of Ad-RTS-hIL-12 and Veledimex by a Quantitative Multiplex Immunoassay for Determination of IL-12 and IFNg Levels

→

outcome · POSTED

Subjects With Ad-RTS-hIL-12 and Veledimex Related Adverse Events Will be Assessed for Safety by CTCAE v5.0

→

outcome · POSTED

Best Overall Response by iRANO Criteria

→

outcome · POSTED

Duration of Response (DOR)

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: 1. Male or female subjects ≤ 21 years-of-age with the demonstrated ability to swallow capsules whole and who are willing to provide access to previously obtained biopsy results 2. Provision of written informed consent and assent, when applicable, for tumor resection, stereotactic surgery, tumor biopsy, sample collection, and/or treatment with study drug prior to undergoing any study-specific procedures 3. Arm 1: Evidence of recurrent or progressive supratentorial tumor, which has shown a \> 25% increase in bi dimensional measurements by MRI or is refractory with significant neuro deterioration that is not otherwise explained with no known curative therapy, not in direct continuity with the ventricular system (e.g., there is physical separation between the tumor and ventricle, the tumor does not open directly into the ventricular system). Arm 2: Clinical presentation of DIPG and compatible MRI with approximately 2/3 of the pons included and without evidence of dissemination. Subjects should be ≥ 2 weeks and ≤ 10 weeks post standard focal radiotherapy (ie, dose of 5400 to 5960 cGy and maximum dexamethasone of 1 mg/m2/day) 4. At the time of registration, subjects must have recovered from the toxic effects of previous treatments, as determined by the treating physician. 1. Targeted agents, including small-molecular tyrosine kinase inhibitors: 2 weeks 2. Other cytotoxic agents: 3 weeks 3. Nitrosoureas: 6 weeks 4. Monoclonal antibody immunotherapies (eg, PD-1, CTLA-4): 6 weeks 5. Vaccine-based and/or viral therapy: 3 months 5. On a stable or decreasing dose of dexamethasone for the previous 7 days 6. Able to undergo standard MRI scans with contrast agent before enrollment and after treatment 7. Have age-appropriate functional performance: 1. Lansky score ≥ 40 or 2. Karnofsky score \> 50 or 3. Eastern Cooperative Oncology Group (ECOG) score ≤ 2 8. Have adequate bone marrow reserves and liver and kidney function, as assessed by the following laboratory requirements: 1. Hemoglobin ≥ 8 g/L 2. Absolute lymphocyte count ≥ 500/mm3 3. Absolute neutrophil count ≥ 1000/mm3 4. Platelets ≥ 100,000/mm3 (untransfused \[\> 5 days\] without growth factors) 5. Serum creatinine ≤ 1.5 x upper limit of normal (ULN) for age 6. Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 x ULN for age 7. Total bilirubin \< 1.5 x ULN for age 8. International normalized ratio (INR) and activated thromboplastin time within normal institutional limits 9. Male and female subjects of childbearing potential must agree to use a highly reliable method of birth control (expected failure rate \< 1% per year) from the Screening visit through 28 days after the last dose of study drug. Women of childbearing potential must have a negative pregnancy test at screening. Exclusion Criteria: 1. Radiotherapy treatment prior to the first veledimex dose: 1. Focal radiation ≤ 4 weeks 2. Whole-brain radiation ≤ 6 weeks 3. Cranio-spinal radiation ≤ 12 weeks NOTE: Subjects in Arm 2 (ie, with DIPG) must be ≥ 2 weeks and ≤ 10 weeks after standard focal radiotherapy (dose of 5400 to 5960 cGy and maximum dexamethasone of 1 mg/m2/day) 2. Subjects with clinically significant increased intracranial pressure (eg, impending herniation or requirement for immediate palliative treatment) or uncontrolled seizures 3. Subjects whose body surface area (BSA) would expose them to \< 75% or \> 125% of the target dose 4. Known immunosuppressive disease, autoimmune condition, and/or chronic viral infection (eg, human immunodeficiency virus \[HIV\], hepatitis) 5. Use of systemic antibacterial, antifungal, or antiviral medications for the treatment of acute clinically significant infection within 2 weeks of first veledimex dose. Concomitant therapy for chronic infections is not allowed. Subjects must be afebrile prior to Ad-RTS-hIL-12 injection; only prophylactic antibiotic use is allowed perioperatively 6. Use of enzyme-inducing antiepileptic drugs (EIAEDs) within 7 days prior to the first dose of study drug 7. Other concurrent clinically active malignant disease, requiring treatment 8. Nursing or pregnant females 9. Prior exposure to veledimex 10. Use of medications that induce, inhibit, or are substrates of cytochrome p450 (CYP450) 3A4 within 7 days prior to veledimex 11. Use of heparin or acetylsalicylic acid (ASA). The use of systemic heparinization, or any ASA containing medications, is prohibited during active dosing with veledimex. Prophylactic heparin SC, per institutional protocol, or heparin when used for maintaining patency of an access port of a PICC line is permitted. 12. Presence of any contraindication for a neurosurgical procedure 13. Unstable or clinically significant concurrent medical condition that would jeopardize the safety of a subject and/or their compliance with the protocol
healthy Volunteers: false
maximum Age: 21 Years
minimum Age: 0 Years
sex: ALL
std Ages: CHILD
ADULT

Treatment arms and interventions

arm Groups

description
Intratumoral Ad-RTS-hIL-12 freehand injection after tumor resection and oral veledimex (activator ligand) in pediatric patients with brain tumors.
intervention Names
Biological: Ad-RTS-hIL-12
Drug: Oral Veledimex - Arm 1 (Pediatric Brain Tumor)
label
Arm 1 - Closed
type
EXPERIMENTAL
description
Intratumoral Ad-RTS-hIL-12 stereotactic injection and oral veledimex (activator ligand) in pediatric patients with DIPG.
intervention Names
Biological: Ad-RTS-hIL-12
Drug: Oral Veledimex - Arm 2 (DIPG)
label
Arm 2 - Open
type
EXPERIMENTAL

interventions

arm Group Labels
Arm 1 - Closed
Arm 2 - Open
description
2.0 x 10\^11 viral particles (vp) per injection, one intratumoral injection of Ad-RTS-hIL-12
name
Ad-RTS-hIL-12
type
BIOLOGICAL
arm Group Labels
Arm 1 - Closed
description
1 dose level (10mg/day) 15 oral daily doses of veledimex
name
Oral Veledimex - Arm 1 (Pediatric Brain Tumor)
type
DRUG
arm Group Labels
Arm 2 - Open
description
2 dose levels (10mg/day, 20mg/day) 14 oral daily doses of veledimex
name
Oral Veledimex - Arm 2 (DIPG)
type
DRUG

Study design

allocation

NON_RANDOMIZED

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 6
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Dose Limiting Toxicities are defined as events that occur during the first 28 days (Day 0 - Day 28) that meets one of the following criteria: * Any local reaction that requires operative intervention and is felt to be attributable to study drug * Any local reaction that has life-threatening consequences requiring urgent intervention or results in death and is felt to be attributable to study drug * Any Grade 3 or higher non-hematologic adverse event that is at least possibly related to study drug and lasts ≥ 3 days * Nausea and vomiting will not be considered a DLT unless at least Grade 3 and refractory to antiemetics * Grade 3 or higher thrombocytopenia (\< 50,000/mm3) at least possibly related to study drug * Any Grade 4 hematologic toxicity (except thrombocytopenia) that is at least possibly related to study drug and lasts ≥ 5 days * Transient neurological changes are expected in Arm 2 and will not be considered a DLT unless they last \> 10 days
measure
The Safety and Tolerability of Intratumoral Ad-RTS-hIL-12 and Veledimex as Measured by Dose Limiting Toxicities and Compliance.
time Frame
From Day 0 through Day 56

secondary Outcomes

description
Veledimex brain concentration. Veledimex plasma concentration was below the limit of quantitation for most patients. Given the limited number of subjects enrolled and early closure of the study, complete assessment of veledimex in blood and brain tumor could not be determined.
measure
To Measure the Veledimex in Blood and Brain Tumor by Using the LC-MS Method
time Frame
From Day 0 through Day 15 of veledimex dosing
description
OS is defined as the duration of time from the first dose of the study drug to the date of death. Subjects were followed for up to 2 years.
measure
Overall Survival (OS)
time Frame
2 Years
description
Samples for serum cytokine analysis were collected on Days 0, 3, 7, 14, and 28. For the results, participants who had samples analyzed were included in the "number analyzed" counts; however, values that were below the limit of quantitation (BLQ) were excluded from the calculation of mean and standard deviation.
measure
Measure Immune Response of Ad-RTS-hIL-12 and Veledimex by a Quantitative Multiplex Immunoassay for Determination of IL-12 and IFNg Levels
time Frame
Day 0, Day 3, Day 7, Day 14, and Day 28
description
Subjects with Ad-RTS-hIL-12 and veledimex related adverse events will be assessed for safety by CTCAE v5.0
measure
Subjects With Ad-RTS-hIL-12 and Veledimex Related Adverse Events Will be Assessed for Safety by CTCAE v5.0
time Frame
2 Years
description
Best Overall Response was assessed using the immunotherapy Response Assessment for Neuro-Oncology (iRANO) criteria.
measure
Best Overall Response by iRANO Criteria
time Frame
2 Years
description
Duration of Response (DOR) was defined as the time from the first documentation of a Complete Response (CR) or Partial Response (PR) to the first documentation of Progressive Disease (PD) or death due to any cause, whichever occurred first.
measure
Duration of Response (DOR)
time Frame
From the time of first response (CR or PR) until progression or death

Full study description

brief Summary: This research study involves an investigational product: Ad-RTS-hIL-12 given with veledimex for production of human IL-12. IL-12 is a protein that can improve the body's natural response to disease by enhancing the ability of the immune system to kill tumor cells and may interfere with blood flow to the tumor. The main purpose of this study is to evaluate the safety and tolerability of a single tumor injection of Ad-RTS-hIL-12 given with oral veledimex in the pediatric population.
detailed Description: Eligible patients will be stratified to one of two arms, according to clinical indication for tumor resection. Pediatric patients who are scheduled for craniotomy and tumor resection will receive one dose of veledimex before the resection procedure. Ad-RTS-hIL-12 will be administered by free-hand injection. Patients will continue on oral veledimex for 14 days. This arm has been completed and is currently closed to enrollment. Pediatric patients with diffuse intrinsic pontine glioma (DIPG) will receive Ad-RTS-hIL-12 by stereotactic injection and then will continue on oral veledimex for 14 days. The study is divided into three periods: the screening period, the treatment period and the follow-up period.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-801a3c3ee46d936f56af
requested nct id
NCT03330197
primary nct id
NCT03330197
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Diffuse+Intrinsic+Pontine+Glioma+%28DIPG%29&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
25fcad6f9e36b53fbec5681d57a4d8fa91f6d5505f2bd8ac1ccfa9650fb620f1
payload sha256
6ee5a2e46941344629db661bf764c1c1e1fa8971ca97edd0ef613ff87d5af62e
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-801a3c3ee46d936f56af
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT03330197
occurrences
context exact
NCT03330197
end
11
exact text
NCT03330197
start
0
offset unit
unicode_code_points
query cond
Diffuse Intrinsic Pontine Glioma (DIPG)
query disease state id
ds-diffuse-intrinsic-pontine-glioma-dipg
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-diffuse-intrinsic-pontine-glioma-dipg-000.json
source file sha256
25fcad6f9e36b53fbec5681d57a4d8fa91f6d5505f2bd8ac1ccfa9650fb620f1
source json pointer
/studies/2/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
be02faf58bc9d0877ebf1f557fc209aa28571a9cc581a1e5224f74ae45efeada
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Diffuse+Intrinsic+Pontine+Glioma+%28DIPG%29&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice